These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30158208)

  • 1. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
    Popova L; Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
    McKelvey K; Baiocchi M; Halpern-Felsher B
    Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of modified risk tobacco product claims on consumer comprehension and risk perceptions of IQOS.
    Yang B; Massey ZB; Popova L
    Tob Control; 2022 Aug; 31(e1):e41-e49. PubMed ID: 33688084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heated tobacco product regulation under US law and the FCTC.
    Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
    Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.
    Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A
    Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceived relative harm of heated tobacco products (IQOS), e-cigarettes, and cigarettes among adults in Canada: Findings from the ITC Project.
    Sutanto E; Miller CR; Smith DM; O'Connor RJ; Gravely S; Hammond D; Hyland A; Cummings KM; Quah ACK; Fong GT; Agar TK; Goniewicz ML
    Tob Induc Dis; 2020; 18():81. PubMed ID: 33013277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corporate communication of the relative health risks of IQOS through a webchat service.
    Braznell S; Branston JR; Gilmore AB
    Tob Control; 2023 Aug; 32(e2):e205-e211. PubMed ID: 35241501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smokers' Exposure to Perceived Modified Risk Claims for E-Cigarettes, Snus, and Smokeless Tobacco in the United States.
    Wackowski OA; O'Connor RJ; Pearson JL
    Nicotine Tob Res; 2021 Feb; 23(3):605-608. PubMed ID: 32812028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.